BUILDING A PRODUCT PIPELINE – ESTABLISHING THE COMMERCIAL POTENTIAL OF NEW PRODUCTS

Absynth有一种开发抗菌疫苗和抗体的创新方法，其基础是识别新的蛋白质抗原，这种抗原利用免疫系统并通过新的双重作用机制发挥作用。对这些产品的需求在一定程度上是由于抗药性菌株的传播。对金黄色葡萄球菌的保护已经取得了原则上的证明，金黄色葡萄球菌是一种在医院和社区引起危及生命的感染的病原体。Absynth技术的一个核心方面是保护主要细菌病原体的蛋白质抗原--在金黄色葡萄球菌中发现的相同靶点在许多其他细菌物种中也存在。在完成了由TSB资助的更广泛市场机会的评估后，AbSynth现在计划对针对另外两种细菌病原体-艰难梭菌和化脓性链球菌-的疫苗进行实验验证，以确定产品潜力。

Absynth has an innovative approach for developing antibacterial vaccines and antibodies, based on a means of identifying novel protein antigens that harness the immune system and work by a novel dual-action mechanism. The need for these products is in part due to the spread of antibiotic resistant strains. Proof of principle has been achieved with protection against Staphylococcus aureus, a pathogen that causes life-threatening infections in hospitals and the community. A central aspect of Absynth’s technology is conservation of the protein antigens across the major bacterial pathogens - the same targets found in S. aureus are present in many other bacterial species. Having completed an assessment of the broader market opportunity, funded by the TSB, Absynth now plans to perform experimental validation of vaccines targeting two other bacterial pathogens, Clostridium difficile and Streptococcus pyogenes to establish the product potential.